Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and disorders involving memory and cognitive function. The company has primarily investigated treatments designed to support synaptic function and neuronal health.

Its lead research program has centered on bryostatin-1, a naturally derived compound being studied for its potential to activate protein kinase C epsilon and improve cognitive function in patients with Alzheimer’s disease. Synaptogenix has also explored potential applications of its technology in other neurological conditions, although its programs remain investigational and the company does not have an established portfolio of approved commercial products.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as it refined its focus on neurodegenerative disease research. Public information identifies Synaptogenix with the Nasdaq ticker SNPX; the ticker symbol TAOX appears to refer to a different issuer. Accordingly, the company and symbol provided should be independently verified before use.

Key Stats

• Today's Range: $3.45 to $3.82
• 50-Day Range: $3.22 to $4.80
• 52-Week Range: $3.07 to $10.00
• Volume: 52,950 shs
• Average Volume: 158,718 shs
• Market Capitalization: $27.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 3% of companies evaluated by MarketBeat, and ranked 871st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Synaptogenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Synaptogenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.47% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 2.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 50.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.37

News Sentiment

Synaptogenix has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Synaptogenix this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.70% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

10.34% of the stock of Synaptogenix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TAOX
• Previous Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.taosynergies.com
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.74 million
• Net Margins: -2,153.97%
• Pretax Margin: -2,153.97%
• Return on Equity: -128.51%
• Return on Assets: -97.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.98
• Quick Ratio: 19.98

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 90.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.83 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 7,850,000
• Free Float: 7,281,000
• Market Cap: $27.28 million
• Optionable: N/A
• Beta: 1.73